Ancora Advisors LLC Makes New $6.98 Million Investment in Enovis Corporation $ENOV

Key Points

• Ancora Advisors purchased 337,144 Enovis shares worth approximately $6.98 million, giving it a 0.58% stake. Institutional investors collectively own 98.45% of the company.
• Enovis exceeded quarterly earnings expectations, reporting $0.90 EPS versus the $0.85 consensus and $582.78 million in revenue, up 3.2% year over year. The company issued fiscal 2026 EPS guidance of $3.52–$3.73.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $41.29, well above the reported share price of $25.61.

Ancora Advisors LLC purchased a new position in shares of Enovis Corporation (NYSE:ENOV - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 337,144 shares of the company's stock, valued at approximately $6,979,000. Ancora Advisors LLC owned about 0.58% of Enovis at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Arax Advisory Partners acquired a new stake in Enovis during the 4th quarter worth $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Allworth Financial LP acquired a new position in shares of Enovis in the second quarter valued at approximately $36,000. Danske Bank A S acquired a new stake in shares of Enovis in the 3rd quarter valued at about $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the 3rd quarter valued at approximately $80,000. 98.45% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company's stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought a total of 4,200 shares of company stock worth $92,084 in the last three months. 2.90% of the stock is owned by company insiders.

Enovis Trading Up 1.6%

NYSE ENOV opened at $25.61 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The business has a 50 day moving average price of $25.39 and a 200-day moving average price of $24.21. Enovis Corporation has a 52 week low of $19.14 and a 52 week high of $34.28. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -1.33 and a beta of 1.34.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analysts' expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis's quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ENOV has been the subject of several recent analyst reports. Evercore set a $32.00 target price on shares of Enovis in a research note on Monday, July 6th. BMO Capital Markets restated an "outperform" rating and set a $30.00 target price on shares of Enovis in a research report on Friday, August 7th. Canaccord Genuity Group dropped their price target on Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, August 17th. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company dropped their price objective on shares of Enovis from $40.00 to $39.00 and set an "overweight" rating for the company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Enovis presently has a consensus rating of "Moderate Buy" and an average price target of $41.29.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.